Home > Back to Publisher > Report Information

Indian Pharmaceutical Industry: Strategies, Trends and Opportunities

Digital Vector
April 1, 2007
352 Pages - SKU: DG1471891

Abstract Table of Contents Search inside this report Related Reports

Countries covered: India

Indian pharmaceutical industry is undergoing fast paced changes. The Indian Generics market is witnessing rapid growth opening up immense opportunities for firms. This is further triggered by the fact that generics worth over $40 billion are going off patent in the coming few years which is close to 15% of the total prescription market of the US. The Indian pharmaceutical companies have been doing extremely well in developed markets such as US and Europe, notable among these being Ranbaxy, Dr. Reddy’s Labs, Wockhardt, Cipla, Nicholas Piramal and Lupin. The companies have their strategies in place to leverage opportunities and appropriate values existing in formulations, bulk drugs, generics, Novel Drug Delivery Systems, New Chemical Entities, Biotechnology etc. The industry ranks fourth globally in terms of volume and in terms of value, it is ranked thirteenth. The industry has thrived so far on reverse engineering skills exploiting the lack of process patent in the country. This has resulted in the Indian pharmaceutical players offering their products at some of the lowest prices in the world. The quality of the products is reflected in the fact that India has the highest number of manufacturing plants approved by US FDA, which is next only to that in the US. Multinational companies have traditionally dominated the industry, which is another trend seeing a reversal. Currently, it is the Indian companies which are dominating the marketplace with the local players dominating a number of key therapeutic segments. The market is also very fragmented with about 30,000 entities and the organized sector consisting of about 300 entities. Consolidation is increasing in the industry with many local players building a global outlook and also growing inorganically through mergers and acquisitions.

Introduction: Market Size of Indian Pharmaceutical Industry; Break-up of the Market; Key Statistics of the Indian Pharmaceutical Industry; Historical Background
Market Overview: Global Pharmaceutical Sector
Characteristics of Indian Pharmaceutical Industry: Market Overview; Segmentation of the Indian Pharmaceutical Industry
Key Emerging Trends: Organised Sector; Unorganised Sector; Collaboration between Indian Firms and Multinationals
Critical Success Factors in the Industry: Research & Development; Production; Marketing, Sales and Distribution; Alliances; Critical Success Factors- Formulations; Critical Success Factors - Bulk Drugs; Post 2005 Critical Success Factors; Critical Success Factors for Indian Companies; Critical Success Factors for Multinationals
Research and Development: Kinds of Research; Bringing Out a Generic Drug; Pharmaceutical R&D Value Chain
Industry Structure: Investments; Exports; Research and Development; Policies and Regulations; Implications of WTO; Intellectual Property Rights (IPR); Changing Scenario of Product Patent Regime; Critic’s View
Marketing & Distribution in Indian Pharmaceutical Industry
The Changing External Environment
Porters Five Forces Model: Threat of New Entrants; Intensity of Competition; Threat of Substitutes; Bargaining Power of Buyers; Bargaining Power of Suppliers
Pharmaceutical Outsourcing in India: Industry Drivers; Pharmaceutical Outsourcing Models; Clinical Trials Outsourcing; Future Directions
Future Outlook for the Indian Pharmaceutical Industry: Strategic Options for Indian Firms; Entering Overseas Markets; Alliance Strategies; Patenting Strategies; Biotechnology; Vaccine Strategies; Implications for MNCs; Product Patents; Industry Profitability; Alternative Medicine; Emerging Trends; Key Growth Barriers for the Industry; Consolidation; Bulk Drug Exports; Imports; Policy Recommendations
Indian Medical Equipments Market: Market for Medical Devices; Industry Trends; Key Market Segments
Indian Healthcare Market: Market Overview; Private Sector; Key Players in the Indian Healthcare Industry
Indian Biotechnology Industry: Market Overview; Projected Market Size of Indian Biotechnology Industry; Industry Growth; Future Developments; Alliances; Indian Bioinformatics Industry

KEY PLAYERS IN THE INDIAN BIOINFORMATICS INDUSTRY
Key Players in the Indian Pharmaceutical Industry
Key Players in the Indian Pharmaceutical Industry
Key Multi National Corporations: Glaxo Smithkline; Pfizer; Novartis; Aventis; Wyeth; Merck
Key Indian Firms in the Indian Pharmaceutical Industry: Ranbaxy; Nicholas Piramal India; Dr. Reddy’s Labs; Cipla; Lupin; Wockhardt
Case of a Leading Pharmaceutial Firm: Ranbaxy Laboratories: History; Ranbaxy’s Successful Report Card; Why Has Ranbaxy Been This Successful?; Evolution of Ranbaxy: Time Line Analysis; Leveraging Mergers & Alliances; Company Acquisitions; Brand Acquisitions; Creating Value through Functional Strategies; Ranbaxy’s Product Strategy; Ranbaxy’s R&D Strategy; Ranbaxy’s Human Resources Strategy; Information Technology
Revenue Model for a Pharmaceutical Company: Strategic Options for Pharmaceutical Firms; How to Build Sustainable Competitive Advantage
Case of a Leading Pharmaceutial Firm: Dr Reddys Labs: Company Background; Branded Generics; International Marketing; People Management; Research & Development; Future
List of Tables: TABLE 1: KEY PHARMACEUTICAL COMPANIES IN INDIA; TABLE 2: LEADING THERAPEUTIC SEGMENTS; TABLE 3: MARKET SHARE OF MAJOR THERAPEUTIC SEGMENTS; TABLE 4: LEADING BRANDS IN MAJOR THERAPEUTIC SEGMENTS; TABLE 5: BRAND ACQUISITIONS IN THE INDIAN PHARMACEUTICAL INDUSTRY; TABLE 6: R&D INVESTMENT OF INDIAN PHARMACEUTICAL COMPANIES; TABLE 7: WHERE INDIA STANDS ON PATENTS; TABLE 8: COST OF DRUG DEVELOPMENT; TABLE 9: COMPARISON OF COSTS OF DRUG DEVELOPMENT; TABLE 10: COMPARISON OF COSTS OF DRUG MANUFACTURING; TABLE 11: CLINICAL TRIAL LABORATORIES IN INDIA; TABLE 12: INDIAN MEDICAL EQUIPMENT MARKET SIZE; TABLE 13: INDIAN HEALTHCARE MARKET STATISTICS; TABLE 14: LIST OF BIOTECHNOLOGY FIRMS IN INDIA; TABLE 15: ALLIANCES BETWEEN INDIAN ENTITIES AND MNC BIOTECHNOLOGY FIRMS; TABLE 16: ALLIANCES BETWEEN INDIAN IT AND INDIAN BIOTECHNOLOGY ENTITIES; TABLE 17: KEY PLAYERS AND THEIR CHARACTERISTICS; TABLE 18: KEY BRANDS OF GLAXO SMITHKLINE IN INDIA; TABLE 19: KEY BRANDS OF PFIZER IN INDIA; TABLE 20: KEY BRANDS OF NOVARTIS IN INDIA; TABLE 21: KEY BRANDS OF AVENTIS IN INDIA; TABLE 22: KEY BRANDS OF WYETH IN INDIA; TABLE 23: KEY BRANDS OF MERCK IN INDIA; TABLE 24: KEY BRANDS OF RANBAXY; TABLE 25: KEY BRANDS OF NICHOLAS PIRAMAL; TABLE 26: KEY BRANDS OF DR REDDY’S; TABLE 27: KEY BRANDS OF CIPLA; TABLE 28: KEY BRANDS OF LUPIN; TABLE 29: KEY BRANDS OF WOCKHARDT; TABLE 30: RANBAXY’S IT INITIATIVES; TABLE 31: TYPICAL PRICE DROPS AFTER A DRUG GOES OFF PATENT
List of Figures: FIGURE 1: MARKET SIZE OF INDIAN PHARMACEUTICAL INDUSTRY; FIGURE 2: VALUE OF PHARMACEUTICAL EXPORTS; FIGURE 3: VALUE OF PHARMACEUTICAL IMPORTS; FIGURE 4: PROJECTED BREAK-UP OF INDIAN PHARMACEUTICAL INDUSTRY; FIGURE 5: VALUE OF BULK DRUG PRODUCTION IN INDIA; FIGURE 6: STRATEGIC GROUP MAPPING OF INDIAN PHARMACEUTICAL INDUSTRY; FIGURE 8: VALUE ADDED BY PHARMACEUTICAL PRODUCTS; FIGURE 9: EVOLUTION OF KNOWLEDGE BASE OF INDIAN PHARMACEUTICAL INDUSTRY; FIGURE 10: DISTRIBUTION CHAIN OF PHARMACEUTICAL COMPANIES IN INDIA; FIGURE 11: PORTER’S 5 FORCES MODEL APPLIED; FIGURE 12: NEW DRUG APPLICATION REVIEW PROCESS WITH THE U.S. FOOD & DRUG ADMINISTRATION; FIGURE 13: SIZE OF INDIAN CLINICAL TRIALS MARKET; FIGURE 14: PATENT EXPIRATION BY THERAPEUTIC CATEGORIES; FIGURE 15: NUMBER OF HOSPITALS IN INDIA; FIGURE 16: NUMBER OF DISPENSARIES IN INDIA; FIGURE 17: NUMBER OF PRIMARY HEALTH CENTRES IN INDIA; FIGURE 18: NUMBER OF HOSPITAL BEDS IN INDIA; FIGURE 19: NUMBER OF DOCTORS IN INDIA; FIGURE 20: MARKET SIZE OF INDIAN BIOTECHNOLOGY INDUSTRY; FIGURE 21: MARKET SIZE OF INDIAN BIOINFORMATICS INDUSTRY; FIGURE 22: MARKET BREAK-UP OF INDIAN BIOINFORMATICS INDUSTRY; FIGURE 23: GLAXO SMITHKLINE INDIA PRODUCT PORTFOLIO; FIGURE 24: PFIZER INDIA PRODUCT PORTFOLIO; FIGURE 25: WYETH INDIA PRODUCT PORTFOLIO; FIGURE 26: MERCK INDIA REVENUE BREAK-UP BASED ON BUSINESS SEGMENTS; FIGURE 27: RANBAXY REVENUE BREAK-UP; FIGURE 28: NICHOLAS PIRAMAL BREAK-UP OF REVENUE FROM FORMULATIONS; FIGURE 29: NICHOLAS PIRAMAL REVENUE BREAK-UP; FIGURE 30: DRL - REVENUE BREAK-UP; FIGURE 31: LUPIN BUSINESS PROFILE; FIGURE 32: LUPIN THERAPEUTIC PORTFOLIO; FIGURE 33: RANBAXY’S FOCUS DURING 1970-EARLY 1980S; FIGURE 34: RANBAXY’S FOCUS DURING 1980-1994; FIGURE 35: RANBAXY’S FOCUS DURING 1994-1997; FIGURE 36: RANBAXY’S FOCUS FROM 1997 ONWARDS; FIGURE 37: VALUE CHAIN OF RANBAXY; FIGURE 38: STRATEGIC OPTIONS AVAILABLE FOR PHARMACEUTICAL FIRMS

More India General Pharmaceuticals Reports

Pharmaceuticals in India by MarketLine
Introduction Pharmaceuticals in India industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2006-10, and forecast to 2015). The profile ...

Special Report: Opportunities in Emerging Markets—Developing Asia by Decision Resources
Asia boasts 6 of the 20 largest economies in the world: China, Japan, India, Russia, Australia, and Indonesia. The countries of developing Asia are all ...

Indian Contract Manufacturing - A Hot Opportunity by RNCOS
The global pharmaceutical contract manufacturing industry has registered strong growth during the past few years. Amongst many other countries adopting the model, India has emerged ...

Strategic Analysis of Contract Research and Manufacturing Services Market in India by Frost & Sullivan
Over the past 2 years the global pharmaceutical industry has been shifting its focus towards the emerging market such as India. The CRAMS segment in ...

Indian Bulk Drug Market by Cygnus Business Consulting and Research
India’s bulk drug industry will reach at US$ 16.91 billion by 2014 at a CAGR of 21%. Bulk drugs are likely to present Indian ...

See all reports like this >>

More India Reports

D&B Country RiskLine Report: India by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: India by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report India January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

India: Country Profile by MarketLine
INTRODUCTION This report provides a detailed analysis on India, providing an overview of its political, economic and business environment, represented both textually and in graph and ...

2007 India Industry & Market Outlook report by Barnes Reports
The 2007 India Industry & Market Outlook report is the leading annual publication that describes over 100 major industries in India and 500+ minor industries ...

See all reports like this >>

Indian Pharmaceutical Industry: Strategies, Trends and Opportunities

Share this report

Other tasks

Research Assistance

Related Markets

General Pharmaceuticals Reports

Free Alert Me service